Author:
Ritchie D. S.,Seymour J. F.,Grigg A. P.,Roberts A. W.,Hoyt R.,Thompson S.,Szer J.,Prince H. M.
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference15 articles.
1. Meusers P, Engelhard M, Bartels H et al (1989) Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 7(5):365–380
2. Howard OM, Gribben JG, Neuberg DS et al (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20(5):1288–1294
3. Teodorovic I, Pittaluga S, Kluin-Nelemans JC et al (1995) Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin’s lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 13(11):2819–2826
4. Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM (1995) A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a southwest oncology group study. Blood 85(4):1075–1082
5. Hiddemann W, Unterhalt M, Dreyling M et al (2002) The addition of rituximab to combination chemotherapy (CT) significantly improves the treatment of mantle cell lymphomas (MCL): results of two prospective randomized studies by the German Low Grade Lymphoma Study Group (GLSG). Blood 100:92a (suppl 1, abstr 339)
Cited by
64 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献